A framework for developing Generic Implant Safety Procedures (GISPs) for scanning patients with medical implants and devices in MRI.

IF 1.8 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING British Journal of Radiology Pub Date : 2024-11-13 DOI:10.1093/bjr/tqae232
Jonathan P Ashmore, Sarah J Prescott, John McLean, Daniel J Wilson, Geoff Charles-Edwards, Peter Wright, David Grainger, Gareth J Barker, Alexandra J Lipton, Rachel Watt, Deepa Gopalan, Mark R Radon
{"title":"A framework for developing Generic Implant Safety Procedures (GISPs) for scanning patients with medical implants and devices in MRI.","authors":"Jonathan P Ashmore, Sarah J Prescott, John McLean, Daniel J Wilson, Geoff Charles-Edwards, Peter Wright, David Grainger, Gareth J Barker, Alexandra J Lipton, Rachel Watt, Deepa Gopalan, Mark R Radon","doi":"10.1093/bjr/tqae232","DOIUrl":null,"url":null,"abstract":"<p><p>UK guidelines for MR safety recommend that MRI departments refer to the implant manufacturer for advice regarding the MRI safety of scanning patients with an implantable medical device prior to scanning [1]. This process of assuring safety can be time consuming, leading to delays and potential cancellations of a patient's MRI. Furthermore, at times the implant cannot be identified, or the implant manufacturers cannot provide up to date MRI safety information. The purpose of generic implant safety procedures (GISPs) is to define a process for managing patients with certain types of implants where the risk from scanning is low. This process incorporates scope for an evidence-based risk-benefit decision to scan some groups of patients under locally-approved conditions, without seeking to identify the exact make and model of the implant and subsequent assurance of MR safety from the implant manufacturer. This publication provides best practice recommendations from a multi-professional working group for the development of these procedures. It is supported by The Institute of Physics and Engineering in Medicine, The Society of Radiographers, The Royal College of Radiologists, The British institute of Radiology, The British Association of MR Radiographers, The International Society of Magnetic Resonance in Medicine British and Irish Chapter and the NHS Scotland MRI Physics Group.</p>","PeriodicalId":9306,"journal":{"name":"British Journal of Radiology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjr/tqae232","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

UK guidelines for MR safety recommend that MRI departments refer to the implant manufacturer for advice regarding the MRI safety of scanning patients with an implantable medical device prior to scanning [1]. This process of assuring safety can be time consuming, leading to delays and potential cancellations of a patient's MRI. Furthermore, at times the implant cannot be identified, or the implant manufacturers cannot provide up to date MRI safety information. The purpose of generic implant safety procedures (GISPs) is to define a process for managing patients with certain types of implants where the risk from scanning is low. This process incorporates scope for an evidence-based risk-benefit decision to scan some groups of patients under locally-approved conditions, without seeking to identify the exact make and model of the implant and subsequent assurance of MR safety from the implant manufacturer. This publication provides best practice recommendations from a multi-professional working group for the development of these procedures. It is supported by The Institute of Physics and Engineering in Medicine, The Society of Radiographers, The Royal College of Radiologists, The British institute of Radiology, The British Association of MR Radiographers, The International Society of Magnetic Resonance in Medicine British and Irish Chapter and the NHS Scotland MRI Physics Group.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
制定通用植入物安全程序 (GISP) 框架,用于在核磁共振成像中扫描装有医疗植入物和设备的患者。
英国磁共振成像安全指南建议,磁共振成像部门在扫描前向植入物制造商咨询有关对植入医疗设备的患者进行磁共振成像扫描的安全性[1]。这一确保安全的过程可能会耗费大量时间,从而导致患者核磁共振成像检查的延迟和潜在取消。此外,有时无法识别植入物,或者植入物制造商无法提供最新的磁共振成像安全信息。通用植入物安全程序 (GISP) 的目的是定义一个流程,用于管理使用某些类型植入物且扫描风险较低的患者。该程序包括在当地批准的条件下对某些患者群体进行扫描的循证风险效益决策范围,而不需要确定植入物的确切品牌和型号,也不需要植入物制造商随后提供磁共振安全保证。本出版物提供了一个多专业工作组为制定这些程序而提出的最佳实践建议。它得到了医学物理与工程研究所、放射技师学会、皇家放射学院、英国放射学会、英国磁共振放射技师协会、国际医学磁共振学会英国和爱尔兰分会以及苏格兰国家医疗服务系统磁共振成像物理小组的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
British Journal of Radiology
British Journal of Radiology 医学-核医学
CiteScore
5.30
自引率
3.80%
发文量
330
审稿时长
2-4 weeks
期刊介绍: BJR is the international research journal of the British Institute of Radiology and is the oldest scientific journal in the field of radiology and related sciences. Dating back to 1896, BJR’s history is radiology’s history, and the journal has featured some landmark papers such as the first description of Computed Tomography "Computerized transverse axial tomography" by Godfrey Hounsfield in 1973. A valuable historical resource, the complete BJR archive has been digitized from 1896. Quick Facts: - 2015 Impact Factor – 1.840 - Receipt to first decision – average of 6 weeks - Acceptance to online publication – average of 3 weeks - ISSN: 0007-1285 - eISSN: 1748-880X Open Access option
期刊最新文献
Children's bone age development is delayed with increasing altitude: a multicentre study. Striving for excellence: multicentre quality improvement project to optimize CT KUB technique in renal colic patients. Assessment of interstitial lung disease in a systemic sclerosis patient cohort using photon-counting detector CT with ultra-high resolution and a 1024-pixel image matrix. Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts. Sister partnership to overcome the global burden of cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1